Aurobindo to manufacture and market molnupiravir
The drug will be marketed under the brand name Molnaflu
The drug will be marketed under the brand name Molnaflu
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Subscribe To Our Newsletter & Stay Updated